Cisplatin cycles treatment sustains cardiovascular and renal damage involving TLR4 and NLRP3 pathways

• Main Authors: Antonio González (Author), Soledad García‐Gómez‐Heras (Author), Raquel Franco‐Rodríguez (Author), Visitación López‐Miranda (Author), Esperanza Herradón (Author)
• Format: Book
• Published: Wiley, 2023-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Cisplatin is clinically proven to combat different cancers, including sarcomas, soft tissue cancers, bones, muscles, and blood. However, renal and cardiovascular toxicities are important limitations in cisplatin therapeutical use. Immunoinflammation could be key factor in cisplatin‐induced...